Abbott Hit With 5 AndroGel Suits In FDA Probe's Wake

Law360, New York (February 5, 2014, 7:14 PM EST) -- Abbott Laboratories Inc. and AbbVie Inc. downplayed the stroke and heart attack risks associated with testosterone replacement treatment AndroGel, according to five lawsuits filed in Illinois federal court Tuesday, just days after the U.S. Food and Drug Administration began investigating the treatment.

The two drugmakers have engaged in an extensive advertising campaign about low testosterone, telling consumers that the natural effects of aging in men, such as listlessness and weight gain, were actually symptoms of the condition that could be treated with their products, according to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.